16 results about "Autoantibody level" patented technology

The present disclosure relates to human antibodies specific to dermatomyositis antigen peptides, preparation methods and uses. Specifically, the present disclosure relates to a monoclonal antibody that specifically binds to MDA5 antigen protein, a preparation method of the monoclonal antibody and a use of the aforementioned monoclonal antibody in the preparation of a drug for the diagnosis, prevention or treatment of inflammatory myopathy or its complications. The antibody or antigen-binding fragment against MDA5 screened by the present disclosure specifically binds to MDA5 antigen, can be used as a reference standard for qualitative detection of MDA5 positivity, realizes qualitative or quantitative detection of the level of anti-MDA5 autoantibody in patients with inflammatory myopathy or its complications, and has important significance for the clinical diagnosis, disease monitoring and treatment of patients with DM, CAMD, DM-ILD, CADM-ILD and the like.

Methods of preparing therapeutic blood products from merged plasma donors are described. Therapeutic blood products include, for example, plasma, plasma proteins, and plasma fractions with improved safety by reducing the concentration of donor autoantibodies against Fc [epsilon] RI [beta] or eliminating such antibodies.

Provided herein are compounds, including compounds of any of the formulae described herein (e.g., Formula (I'), Formula (I), Formula (II)), and pharmaceutically acceptable salts thereof. Compounds provided herein are capable of covalently binding to and inhibiting neonatal fragment crystallizable receptor (FcRn) proteins and are therefore useful in the treatment and / or prevention of various diseases, including conditions associated with FcRn activity and / or immunoglobulin G (IgG) autoantibody levels in a subject.

A method for preparing therapeutic blood products from pooled plasma donors is provided. The therapeutic blood products include, for example, plasma, plasma proteins, and plasma fractions, in which safety is improved by reducing or eliminating the concentration of donor autoantibodies against FcεRIβ.

The invention relates to a humanized antibody of a dermatomyositis specific antigen as well as a preparation method and application of the humanized antibody. Amino acid sequences of HCDR1, HCDR2 and HCDR3 of a heavy chain of the antibody respectively comprise sequences as shown in SEQ ID No.6 to SEQ ID No.8, and amino acid sequences of LCDR1, LCDR2 and LCDR3 of a light chain of the antibody respectively comprise a sequence as shown in SEQ ID No.9, a sequence as shown in GQD and a sequence as shown in SEQ ID No.10. The anti-MDA5 human monoclonal antibody obtained through screening is high in activity, good in stability and high in MDA5 binding specificity, can serve as a reference standard for qualitative detection of MDA5 positive, can also be used for quantitative detection of the anti-MDA5 autoantibody level in patients suffering from inflammatory myopathy or complications of the inflammatory myopathy, and can be used for clinical application. And a new tool is provided for diagnosis, monitoring, treatment and the like of dermatomyositis and complications thereof.

The present invention belongs to the field of biomedicine, and provides an antibody for recognizing TIF1-γ and its application. The amino acid sequence of the heavy chain variable region of the antibody is as shown in SEQ ID NO: 1; the amino acid sequence of the light chain variable region is as shown in SEQ ID NO: 5; the heavy chain variable region includes CDR1 as shown in SEQ ID NO: 2, CDR2 as shown in SEQ ID NO: 3, and CDR3 as shown in SEQ ID NO: 4; the light chain variable region includes CDR1 as shown in SEQ ID NO: 6, CDR2 is DVN, and CDR3 as shown in SEQ ID NO: 7. The antibody of the present invention has the characteristics of good specificity and strong affinity, can be used for quantitatively detecting the level of anti-TIF1-γ autoantibody in DM patients, so as to monitor the disease activity, and can be used for the clinical diagnosis of DM patients.

Provided herein are cyclic peptides capable of binding to and inhibiting neonatal fragment crystallizable receptor (FcRn) proteins, and methods of using the same for the treatment and / or prevention of various diseases, including conditions associated with FcRn activity and / or immunoglobulin G (IgG) autoantibody levels in a subject.

The present invention belongs to the field of biomedical technology, and provides an antibody or its antigen-binding fragment that specifically binds to the TIF1-γ protein and its application. The heavy-chain variable region of the antibody or its antigen-binding fragment comprises CDR1 as shown in SEQ ID NO:1, CDR2 as shown in SEQ ID NO:2, and CDR3 as shown in SEQ ID NO:3; the light-chain variable region of the antibody or its antigen-binding fragment comprises CDR1 as shown in SEQ ID NO:6, the amino acid sequence of CDR2 is DDS, and CDR3 as shown in SEQ ID NO:7. The antibody screened in the present invention has high activity, good stability, and strong specificity; the antibody can quantitatively detect the level of anti-TIF1-γ autoantibodies in DM patients, and has important value in the development of a kit for detecting idiopathic inflammatory myopathy.

Provided herein are cyclic peptides capable of covalently binding to and inhibiting neonatal fragment crystallizable receptor (FcRn) proteins, and methods of using the same for the treatment and / or prevention of various diseases, including conditions associated with FcRn activity and / or immunoglobulin G (IgG) autoantibody levels in a subject.

The invention belongs to the field of biological medicine, and provides an antibody for identifying TIF1-gamma and application thereof, and the amino acid sequence of a heavy chain variable region of the antibody is shown as SEQ ID NO: 1; the amino acid sequence of the light chain variable region is as shown in SEQ ID NO: 5; the heavy chain variable region comprises a CDR1 as shown in SEQ ID NO: 2, a CDR2 as shown in SEQ ID NO: 3 and a CDR3 as shown in SEQ ID NO: 4; the light chain variable region comprises CDR1 as shown in SEQ ID NO: 6, CDR2 is DVN, and CDR3 as shown in SEQ ID NO: 7. The antibody disclosed by the invention has the characteristics of good specificity and strong affinity, can be used for quantitatively detecting the level of the anti-TIF1-gamma autoantibody in a DM patient so as to monitor the illness state activity, and can be used for clinical diagnosis of the DM patient.

The present invention belongs to the technical field of biomedicine, and provides an anti-TIF1-γ monoclonal antibody and its application. The present invention uses phage antibody library technology to screen out a human-derived anti-TIF1-γ monoclonal antibody with good specificity and strong affinity. By specifically binding to TIF1-γ, the antibody can quantitatively detect the level of anti-TIF1-γ autoantibodies in DM patients, thereby monitoring the disease activity, and can be used for the clinical diagnosis of DM patients. The research of the present invention provides a theoretical and experimental basis for the specific treatment of DM, and also provides a new research direction for the treatment of autoimmune diseases with autoantibodies as the main pathogenic mechanism.

The present invention discloses the use of puerarin in the preparation of a drug for preventing and / or treating Hashimoto's thyroiditis. Puerarin can effectively improve the Hashimoto's phenotype. The present invention proves through experiments that puerarin effectively inhibits the inflammatory damage of thyroid tissue and suppresses the level of autoantibodies, with significant differences compared with the control group, and has a good therapeutic effect on Hashimoto's thyroiditis.

The invention belongs to the technical field of biological medicine, and provides an anti-TIF1-gamma monoclonal antibody and application thereof.The human-derived anti-TIF1-gamma monoclonal antibody good in specificity and high in affinity is screened out through a phage antibody library technology, the antibody is specifically combined with TIF1-gamma, and the TIF1-gamma monoclonal antibody with high affinity is obtained. The anti-TIF1-gamma autoantibody level in a DM patient can be quantitatively detected, so that the illness state activity degree is monitored, and the kit can be used for clinical diagnosis of the DM patient. The research of the invention provides theoretical and experimental basis for specific treatment of DM, and also provides a new research direction for treatment of autoimmune diseases with autoantibodies as main pathogenic mechanisms.

The present disclosure belongs to the field of biological medicine, and relates to a human antibody binding to a BP specific antigen peptide, a preparation method and use. Specifically, the present disclosure relates to a monoclonal antibody, wherein the antibody specifically binds to the NC16A domain of the BP180 antigen protein, a preparation method of the monoclonal antibody, and use of the aforementioned monoclonal antibody in preparation of a drug for diagnosis, prevention or treatment of bullous pemphigoid. The antibody or antigen binding fragment against BP180 screened by the present disclosure specifically binds to the BP180 antigen, can be used as a reference standard for qualitative detection of BP180 positivity, realizes quantitative detection of the level of the anti-BP180 NC16A autoantibody in BP patients, and has important significance for clinical diagnosis, disease monitoring and treatment of the BP patients.

Provided herein are cyclic peptides capable of binding to and inhibiting neonatal fragment crystallizable receptor (FcRn) proteins, and methods of using the same for the treatment and / or prevention of various diseases, including conditions associated with FcRn activity and / or immunoglobulin G (IgG) autoantibody levels in a subject.

Methods for treating systemic lupus erythematosus using compounds or pharmaceutical compositions that modulate the activity of Bcl-2 family proteins are disclosed. In some methods, the patient to be treated is diagnosed with lupus nephritis. In some methods, the compound or pharmaceutical composition is administered to the patient in need thereof at a therapeutically effective dose sufficient to elicit one or more effects selected from: reduced excretion of protein in the urine of the patient, reduced serum anti-dsDNA autoantibody levels in the patient, reduced skin lesion severity in the patient, reduced lymphadenopathy severity in the patient, reduced glomerulonephritis severity in the patient, reduced vasculitis severity in the patient, reduced lymphocyte cell counts in a peripheral blood mononuclear cell (PMBC) panel taken from the patient, reduced lymphocyte cell counts in the spleen of the patient, and reduced lymphocyte infiltration of the kidneys of the patient.